(redirected from ribonucleic acid)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to ribonucleic acid: deoxyribonucleic acid, ATP
References in periodicals archive ?
Conclusion: Micro ribonucleic acid 34-a might suppress the progression of neuroblastoma through inhibiting the expression of the potential target gene CD44.
Conclusion: Interferon alpha receptors 1-messenger ribonucleic acid may be useful for predicting response to interferon plus ribavirin therapy in hepatitis C virus/ hepatitis B virus co-infected patients who were females with lower hepatitis C virus-ribonucleic acid and hepatitis B virus-deoxyribonucleic acid levels.
Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative ribonucleic acid interference-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases.
RXi Pharmaceuticals, which focuses on using ribonucleic acid to block the action of genes in cells, had a strong opening act.
A new study provides evidence that recently discovered ribonucleic acid segments may become plum targets.
Specifically, the RNA molecules of the present invention are double-stranded ribonucleic acid molecules (dsRNA).
Factors associated with the development of liver disease in these patients included testing positive for HCV ribonucleic acid, age greater than 39 years at the time of infection, and the number of years since transfusion.
Tests have shown a significant increase in the synthesis activity of ribonucleic acid, a function of the liver, leading researchers to conclude that the bone marrow cells were transforming into liver cells, they said.
Micro ribonucleic acid (RNA) - or miR - is found in all living organisms and are considered as small single-stranded RNAs made up of 18-20 nucleotides which are derivatives of post-transcription.
US-based investigational ribonucleic acid interference therapeutics developer Dicerna Pharmaceuticals, Inc.
256/2015 race - open procedure for the three-year supply, renewable for a further two years, systems for diagnostics of deoxyribonucleic acid of human cytomegalovirus infections, deoxyribonucleic acid of the human type c hepatitis, virus deoxyribonucleic acid dell ~ human hepatitis b, and ribonucleic acid of the acquired human immunodeficiency virus type 1 with car instrumentation.